Here’s my piece for the National Post, reflecting on the lessons of 2020.
Can Canada Innovate?
Canada has a profound cultural resistance to innovation, and reinforces that through counter-productive policies. Health care is one of the least innovative fields, and Canada does all it can to keep it that way. My recent op-ed in the Financial Post is here.
More bad ideas in drug price regulation
The federal government persists in putting forward ideas to make drugs less available and Canadians sicker. Now the US is upping the ante with ideas of its own. My Financial Post op-ed here.
Should we give it away?
Drug and medical device firms are giving stuff away in the face of the pandemic. Why? My latest op-ed is here.
Depressing drug prices is a bad idea
This is my latest editorial for the financial post on how damaging drug price controls are for the health of Canadians.
WHO’S AFRAID OF THE USMCA? Why the intellectual property provisions in the US Mexico Canada Agreement are good for Canada and its trading partners
My recent paper for MLI can be found here.
Ignore the naysayers. The new USMCA deal is great for Canadian innovators
See my latest from the Financial Post here.
Take notice copyright infringers: Canadian courts still think intellectual-property laws matter
While legislators and academics try to weaken Canada’s intellectual property laws, the courts know better; recent judgements cleave to sound IP doctrine. My op-ed for the Financial Post is here.
.
Trudeau Government is Building a Wall to Keep Out Life-Saving Drugs
My Financial Post editorial on the proposed changes to the regulations governing the Patented Medicines Price Review Board is here.
.